Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 bln doses
The Peninsula
BEIJING: A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses.
The Wuhan Institute of Biological Products made the announcement in a statement released late on Monday through social media. It did not specify when it will operate the factory at full capacity. Still, the announcement marks a step toward state-backed Sinopharm's annual capacity target of 3 billion doses for its COVID-19 vaccines.More Related News